Financial News
Latest News about Schizophrenia
Recent news which mentions Schizophrenia
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
November 11, 2024
From Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
October 07, 2024
From Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 30, 2024
From Benzinga
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
June 12, 2023
Tickers
PMBHF
From Benzinga
Psychedelics And Schizophrenia: What's The Link?
February 19, 2023
From Benzinga
Tips on Managing Your Schizophrenia
August 22, 2022
Tickers
ALKS
Marketing & Marijuana: Why Responsibility Is So Important As Psychosis & Schizophrenia Among Youth Rise
June 08, 2022
From Benzinga
Addex Expands Pipeline With Selective M4 PAM Program For Schizophrenia & Other Psychotic Disorders
April 06, 2022
Tickers
ADXN
From Benzinga
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
February 24, 2022
Tickers
KRTX
From Benzinga
Cannabis Increases Odds Of This Disorder In Teens Despite Infrequent Use
February 08, 2022
From Benzinga
Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia
February 08, 2022
Tickers
ALKS
From Benzinga
Alkermes Highlights Signs and Symptoms of Schizophrenia
January 31, 2022
FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders
December 01, 2021
Tickers
BTAI
From Benzinga
Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets
November 22, 2021
Tickers
NBIX
From Benzinga
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
November 01, 2021
Tickers
TEVA
From Benzinga
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
September 30, 2021
Tickers
NERV
From Benzinga
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program
September 13, 2021
Tickers
ALKS
FDA Approves First And Only Twice-Yearly Schizophrenia Drug
September 01, 2021
Tickers
JNJ
From Benzinga
Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review
September 01, 2021
Tickers
TEVA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
